Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cet article présente les recommandations de l'"European Society for Medical Oncology" concernant le diagnostic et le traitement d'un myélome multiple ainsi que le suivi médical des patients
Multiple myeloma (MM) accounts for 1% of all cancers and ∼10% of all haematological malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at diagnosis of between 65 and 70 years; the mortality is 4.1/100 000/year. Almost all patients with MM evolve from an asymptomatic pre-malignant stage termed monoclonal gammopathy of undetermined significance (MGUS). MGUS progresses to MM at a rate of 1% per year. In some patients, an intermediate asymptomatic but more advanced pre-malignant stage termed smouldering (or indolent) multiple myeloma (SMM) can be recognised. SMM progresses to myeloma at a rate of 10% per year over the first 5 years following diagnosis, 3% per year over the following 5 years and 1.5% per year thereafter...
Annals of Oncology , article en libre accès, 2013